El trading conlleva riesgos
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Bio-Techne Corp
Cerrado
SectorSanidad
50.09 -0.71
Resumen
Variación precio
24h
Mínimo
49.62
Máximo
51.04
Ingresos | -12M 23M |
|---|---|
Ventas | 19M 316M |
P/B Media del Sector | 66.121 34.393 |
Rentabilidad por dividendo | 0.58 |
Margen de beneficios | 7.144 |
Empleados | 3,100 |
EBITDA | -7.1M 68M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 Meses | +27.44% upside |
Rentabilidad por dividendo Media del Sector | 0.58% 2.54% |
|---|---|
Próximas Ganancias | 29 oct 2025 |
Fecha Próximo Dividendo | 29 ago 2025 |
Próxima Fecha de Ex Dividendo | 18 ago 2025 |
Capitalización Mercado | -1.9B 8.6B |
|---|---|
Apertura anterior | 50.8 |
Cierre anterior | 50.09 |
Noticias sobre sentimiento de mercado
By Acuity
61%
39%
326 / 374 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Weak Bullish Evidence
Bio-Techne Corp Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Bio-Techne Corp previsión
Precio Objetivo
By TipRanks
27.44% repunte
Estimación a 12 Meses
Media 63.91 USD 27.44%
Máximo 75 USD
Mínimo 53 USD
De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bio-Techne Corp Dist en los últimos 3 meses.
Sentimiento
By Acuity
326 / 374 Clasificación en Sanidad
Noticias sobre sentimiento de mercado
Coyuntura bajista
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
